Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration
CANACTFAST
A Multicenter, 12 Week Treatment Single Step Titration Open-Label Study Assessing The % Of Patients Achieving Ldl-C Target With Atorvastatin Starting Doses Of 10mg, 20mg, 40mg and 80mg.
1 other identifier
interventional
1,100
1 country
84
Brief Summary
The objective of this study is to assess the effectiveness of an atorvastatin treatment regimen involving starting doses between 10 and 80 mg, followed by a single-step titration (except for subjects started at 80mg), if required
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jun 2004
Shorter than P25 for phase_3
84 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 6, 2005
CompletedFirst Posted
Study publicly available on registry
September 8, 2005
CompletedFebruary 18, 2021
February 1, 2021
September 6, 2005
February 17, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion (%) of subjects achieving their LDL-C target after 12 weeks of treatment according to their 10-year CHD risk category (based on the new canadian guidelines on the management and treatment of dyslipidemia).
Secondary Outcomes (1)
The global proportion (%) of patients reaching targets when risk categories are combined The proportion (%) of subjects achieving BOTH their LDL-C and TC/HDL-C ratio targets after 6 and 12 weeks of treatment, globally and according to their 10-year
Interventions
Eligibility Criteria
You may qualify if:
- Age 30 to 79 years old
- Triglyceride level 6.8 mmol/L at screening
- LDL-C of 5.7 mmol/L at screening
You may not qualify if:
- Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception. The latter are defined as: abstinence, surgical sterilization, oral contraceptives for at least 3 cycles, intrauterine device, implant, depot injection, or barrier method in conjunction with contraceptive foam or jelly.
- Subjects whose blood cholesterol levels are controlled (LDL-C targets) with statins other than atorvastatin
- Subjects receiving statin doses higher than the following: 10-40mg for simvastatin , 20-40mg for fluvastatin, pravastatin and lovastatin and 10-20 mg for rosuvastatin. Subjects already treated with atorvastatin at the time of screening are not eligible unless atorvastatin has been discontinued at least 2 months prior to screening
- Subjects receiving 2 or more lipid lowering agents are excluded (statins + resins or fibrates or niacin or fish oils)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (84)
Pfizer Investigational Site
Calgary, Alberta, T2E 7C5, Canada
Pfizer Investigational Site
Calgary, Alberta, T3E 0C5, Canada
Pfizer Investigational Site
Calgary, Alberta, T3G 3J9, Canada
Pfizer Investigational Site
Edmonton, Alberta, T5A 4L8, Canada
Pfizer Investigational Site
Edmonton, Alberta, T5K 2A2, Canada
Pfizer Investigational Site
Edmonton, Alberta, T5N 2N8, Canada
Pfizer Investigational Site
Coquitlam, British Columbia, V3K 3P4, Canada
Pfizer Investigational Site
Coquitlam, British Columbia, V3K 3V9, Canada
Pfizer Investigational Site
Kelowna, British Columbia, V1Y 2H4, Canada
Pfizer Investigational Site
Langley, British Columbia, V3A 4H9, Canada
Pfizer Investigational Site
Surrey, British Columbia, V3R 3P1, Canada
Pfizer Investigational Site
Vancouver, British Columbia, V5Z 3J5, Canada
Pfizer Investigational Site
Victoria, British Columbia, V8T 3P2, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, R2V 3P4, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1R9, Canada
Pfizer Investigational Site
Moncton, New Brunswick, E1G 1A7, Canada
Pfizer Investigational Site
Rothesay, New Brunswick, E2E 2R2, Canada
Pfizer Investigational Site
Saint John, New Brunswick, E2K 2T8, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, B3H 1Y6, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, B3K 5R3, Canada
Pfizer Investigational Site
Halifax, B3K 5R3, Nova Scotia, Canada
Pfizer Investigational Site
Brampton, Ontario, L6T 3J1, Canada
Pfizer Investigational Site
Burlington, Ontario, L7M 4Y1, Canada
Pfizer Investigational Site
Courtice, Ontario, L1E 3C3, Canada
Pfizer Investigational Site
Downsview, Ontario, M3M 3E5, Canada
Pfizer Investigational Site
Fort Erie, Ontario, L2A1Z3, Canada
Pfizer Investigational Site
Hamilton, Ontario, L8M 1K7, Canada
Pfizer Investigational Site
Hawkesbury, Ontario, K6A 1A1, Canada
Pfizer Investigational Site
Kitchener, Ontario, N2C 2N9, Canada
Pfizer Investigational Site
Lindsay, Ontario, K9V 6C5, Canada
Pfizer Investigational Site
Markham, Ontario, L6B 1A1, Canada
Pfizer Investigational Site
Midland, Ontario, L4R 4P4, Canada
Pfizer Investigational Site
Napanee, Ontario, K7R 2G3, Canada
Pfizer Investigational Site
Newmarket, Ontario, L3Y 5G8, Canada
Pfizer Investigational Site
Niagara Falls, Ontario, L2E 7H1, Canada
Pfizer Investigational Site
North Bay, Ontario, P1B 2H3, Canada
Pfizer Investigational Site
North York, Ontario, M3J 1N2, Canada
Pfizer Investigational Site
Oshawa, Ontario, L1H 1B9, Canada
Pfizer Investigational Site
Oshawa, Ontario, L1J 2K9, Canada
Pfizer Investigational Site
Ottawa, Ontario, K1C 1S6, Canada
Pfizer Investigational Site
Saint Catherines, Ontario, L2N 7H8, Canada
Pfizer Investigational Site
Saint Catherines, Ontario, L2S 3V7, Canada
Pfizer Investigational Site
Sarnia, Ontario, N7T 4X3, Canada
Pfizer Investigational Site
Thornhill, Ontario, L3T 4X1, Canada
Pfizer Investigational Site
Thunder Bay, Ontario, P7E 4Z3, Canada
Pfizer Investigational Site
Thunder Bay, Ontario, P7E 6E7, Canada
Pfizer Investigational Site
Toronto, Ontario, M5C 2T2, Canada
Pfizer Investigational Site
Toronto, Ontario, M5G 2C4, Canada
Pfizer Investigational Site
Toronto, Ontario, M8V 3X8, Canada
Pfizer Investigational Site
Toronto, Ontario, M9W 4L6, Canada
Pfizer Investigational Site
Windsor, Ontario, N8X 1K4, Canada
Pfizer Investigational Site
Charlottetown, Prince Edward Island, C1A 1L2, Canada
Pfizer Investigational Site
Montague, Prince Edward Island, C0A 1R0, Canada
Pfizer Investigational Site
Amos, Quebec, J9T 1T8, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, G7H 5H6, Canada
Pfizer Investigational Site
Cowansville, Quebec, J2K 2X9, Canada
Pfizer Investigational Site
Greenfield Park, Quebec, J4V 2G8, Canada
Pfizer Investigational Site
Greenfield Park, Quebec, J4V 2H1, Canada
Pfizer Investigational Site
Greenfield Park, Quebec, J4V2H1, Canada
Pfizer Investigational Site
Laval, Quebec, H7N 2k2, Canada
Pfizer Investigational Site
Laval, Quebec, H7T 2P5, Canada
Pfizer Investigational Site
Laval, Quebec, H7V 2W3, Canada
Pfizer Investigational Site
Le Gardeur, Quebec, J5Z 3C4, Canada
Pfizer Investigational Site
Montreal, Quebec, H3A 1A1, Canada
Pfizer Investigational Site
Montreal, Quebec, H3S 2W1, Canada
Pfizer Investigational Site
Montreal, Quebec, H4N 2W2, Canada
Pfizer Investigational Site
Montreal, Quebec, H4V 2R8, Canada
Pfizer Investigational Site
Plessisville, Quebec, G6L 3J1, Canada
Pfizer Investigational Site
Québec, Quebec, G1S 2L6, Canada
Pfizer Investigational Site
Saint-Eustache, Quebec, J7P 2V1, Canada
Pfizer Investigational Site
Saint-Léonard, Quebec, H1S 3A9, Canada
Pfizer Investigational Site
Salaberry Du Valleyfield, Quebec, J6S 4Z5, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, J1H 4J6, Canada
Pfizer Investigational Site
Ste. Foy, Quebec, G1V 4G2, Canada
Pfizer Investigational Site
Vaudreuil, Quebec, J7V 8P9, Canada
Pfizer Investigational Site
Regina, Saskatchewan, S4P 3X1, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7H 0W6, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7K 0H6, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7K 1N8, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7K 7H9, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7L 2W1, Canada
Pfizer Investigational Site
St. John's, A1E 2C2, Canada
Pfizer Investigational Site
St. John's, A1E 2E2, Canada
Related Publications (1)
Ur E, Langer A, Rabkin SW, Calciu CD, Leiter LA; CanACTFAST Study Investigators. Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. Can J Cardiol. 2010 Feb;26(2):80-6. doi: 10.1016/s0828-282x(10)70003-9.
PMID: 20151053DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 6, 2005
First Posted
September 8, 2005
Study Start
June 1, 2004
Study Completion
May 1, 2005
Last Updated
February 18, 2021
Record last verified: 2021-02